Mi-2β promotes immune evasion in melanoma by activating EZH2 methylation
© 2024. The Author(s)..
Recent development of new immune checkpoint inhibitors has been particularly successfully in cancer treatment, but still the majority patients fail to benefit. Converting resistant tumors to immunotherapy sensitive will provide a significant improvement in patient outcome. Here we identify Mi-2β as a key melanoma-intrinsic effector regulating the adaptive anti-tumor immune response. Studies in genetically engineered mouse melanoma models indicate that loss of Mi-2β rescues the immune response to immunotherapy in vivo. Mechanistically, ATAC-seq analysis shows that Mi-2β controls the accessibility of IFN-γ-stimulated genes (ISGs). Mi-2β binds to EZH2 and promotes K510 methylation of EZH2, subsequently activating the trimethylation of H3K27 to inhibit the transcription of ISGs. Finally, we develop an Mi-2β-targeted inhibitor, Z36-MP5, which reduces Mi-2β ATPase activity and reactivates ISG transcription. Consequently, Z36-MP5 induces a response to immune checkpoint inhibitors in otherwise resistant melanoma models. Our work provides a potential therapeutic strategy to convert immunotherapy resistant melanomas to sensitive ones.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Nature communications - 15(2024), 1 vom: 09. März, Seite 2163 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Li, Cang [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
DNA Helicases |
|---|
| Anmerkungen: |
Date Completed 11.03.2024 Date Revised 28.03.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41467-024-46422-5 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369510291 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369510291 | ||
| 003 | DE-627 | ||
| 005 | 20240329000729.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240310s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41467-024-46422-5 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1353.xml |
| 035 | |a (DE-627)NLM369510291 | ||
| 035 | |a (NLM)38461299 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Li, Cang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Mi-2β promotes immune evasion in melanoma by activating EZH2 methylation |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.03.2024 | ||
| 500 | |a Date Revised 28.03.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a Recent development of new immune checkpoint inhibitors has been particularly successfully in cancer treatment, but still the majority patients fail to benefit. Converting resistant tumors to immunotherapy sensitive will provide a significant improvement in patient outcome. Here we identify Mi-2β as a key melanoma-intrinsic effector regulating the adaptive anti-tumor immune response. Studies in genetically engineered mouse melanoma models indicate that loss of Mi-2β rescues the immune response to immunotherapy in vivo. Mechanistically, ATAC-seq analysis shows that Mi-2β controls the accessibility of IFN-γ-stimulated genes (ISGs). Mi-2β binds to EZH2 and promotes K510 methylation of EZH2, subsequently activating the trimethylation of H3K27 to inhibit the transcription of ISGs. Finally, we develop an Mi-2β-targeted inhibitor, Z36-MP5, which reduces Mi-2β ATPase activity and reactivates ISG transcription. Consequently, Z36-MP5 induces a response to immune checkpoint inhibitors in otherwise resistant melanoma models. Our work provides a potential therapeutic strategy to convert immunotherapy resistant melanomas to sensitive ones | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Enhancer of Zeste Homolog 2 Protein |2 NLM | |
| 650 | 7 | |a EC 2.1.1.43 |2 NLM | |
| 650 | 7 | |a EZH2 protein, human |2 NLM | |
| 650 | 7 | |a EC 2.1.1.43 |2 NLM | |
| 650 | 7 | |a Immune Checkpoint Inhibitors |2 NLM | |
| 650 | 7 | |a Mi-2beta protein, mouse |2 NLM | |
| 650 | 7 | |a EC 3.6.1.3 |2 NLM | |
| 650 | 7 | |a DNA Helicases |2 NLM | |
| 650 | 7 | |a EC 3.6.4.- |2 NLM | |
| 700 | 1 | |a Wang, Zhengyu |e verfasserin |4 aut | |
| 700 | 1 | |a Yao, Licheng |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Xingyu |e verfasserin |4 aut | |
| 700 | 1 | |a Jian, Yongping |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Yujia |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Jie |e verfasserin |4 aut | |
| 700 | 1 | |a Shao, Jingwei |e verfasserin |4 aut | |
| 700 | 1 | |a Tran, Phuc D |e verfasserin |4 aut | |
| 700 | 1 | |a Hagman, James R |e verfasserin |4 aut | |
| 700 | 1 | |a Cao, Meng |e verfasserin |4 aut | |
| 700 | 1 | |a Cong, Yusheng |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Hong-Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Goding, Colin R |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Zhi-Xiang |e verfasserin |4 aut | |
| 700 | 1 | |a Liao, Xuebin |e verfasserin |4 aut | |
| 700 | 1 | |a Miao, Xiao |e verfasserin |4 aut | |
| 700 | 1 | |a Cui, Rutao |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nature communications |d 2010 |g 15(2024), 1 vom: 09. März, Seite 2163 |w (DE-627)NLM199274525 |x 2041-1723 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2024 |g number:1 |g day:09 |g month:03 |g pages:2163 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41467-024-46422-5 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2024 |e 1 |b 09 |c 03 |h 2163 | ||